Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: A PRO/CON Debate.

Provencio M; Couñago F

doi:10.1016/j.arbres.2025.09.015

← 뒤로

Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: A PRO/CON Debate.

0/5 보강

Archivos de bronconeumologia 2026 Vol.62(3) p. 150-153

Provencio M, Couñago F

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Provencio M, Couñago F (2026). Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: A PRO/CON Debate.. Archivos de bronconeumologia, 62(3), 150-153. https://doi.org/10.1016/j.arbres.2025.09.015

MLA Provencio M, et al.. "Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: A PRO/CON Debate.." Archivos de bronconeumologia, vol. 62, no. 3, 2026, pp. 150-153.

PMID 41093734 ↗

DOI 10.1016/j.arbres.2025.09.015

같은 제1저자의 인용 많은 논문 (3)

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.
Nature cancer 2026
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.
Nature communications 2025